New York's legal cannabis market has crossed $3.3 billion in cumulative sales since the first dispensary opened in December 2022. As of yesterday's Cannabis Control Board meeting, the state has issued 2,204 adult-use licenses and counts 623 operational dispensaries statewide. Year-over-year sales growth stands at 54.8% — the highest among large U.S. cannabis markets, at a moment when California and Colorado are posting declines.
These are not projections. These are verified figures sourced from the Office of Cannabis Management, the Cannabis Control Board, and third-party market analytics. What they reveal is a market moving at extraordinary velocity — and a set of structural pressures scaling just as fast.
The License Landscape
Yesterday's CCB meeting approved 27 new adult-use licenses, bringing the statewide total to 2,204. The breakdown: 246 cultivators, 234 distributors, 324 microbusinesses, 540 processors, 519 retail dispensaries, and 341 CAURD licenses. Additionally, the board adopted regulations for cannabis showcase events — a new framework allowing licensed sales outside traditional dispensaries.
The scale of licensing acceleration is significant. In September 2025, the total stood at 1,904. Six months later, the state has added 300 licenses. But the more telling number is the gap between licenses issued and dispensaries actually open: 2,204 licenses exist, but only 623 dispensaries are operational. That means 71.7% of the licensed retail base has not yet opened for business.
2,204 licenses issued. 623 dispensaries open. The conversion rate from license to operational storefront is 28.3%. The bottleneck is no longer regulatory. It is real estate, capital, and buildout.
The constraint has shifted. In 2023 and 2024, the bottleneck was licensing — lawsuits, processing delays, and regulatory uncertainty kept the market suppressed. In 2026, the bottleneck is execution. Operators have licenses but face compressed retail real estate in Manhattan, rising buildout costs, and a capital environment that remains hostile to cannabis businesses under Section 280E.
Revenue Velocity
The sales trajectory tells a clear story of acceleration. Annual retail sales: $317 million in 2023, $1.0 billion in 2024, $1.69 billion in 2025. February 2026 alone produced $163.5 million in monthly sales. OCM projects $2.6 billion by end of year, with forecasts reaching $3.7 billion annually by 2027.
Among large U.S. cannabis markets, no state is growing faster. New York's 54.8% year-over-year growth dwarfs every established market. California posted -6.4%. Colorado posted -8.4%. Michigan, the only other large market still growing, trails New York significantly in growth rate.
But growth and health are not the same thing. Average item prices have fallen from $35.41 to $31.29 over the past year — an 11.6% decline. New York's prices remain among the highest nationally (Michigan averages $8.88, California $18.44), but the compression is accelerating. As more dispensaries open and product variety increases, the premium pricing that early operators relied on is eroding.
Revenue is growing. Margins are not. Operators are scaling sales while Section 280E, price compression, and rising compliance costs constrain profitability. The market's top-line story is not its bottom-line reality.
The Equity Framework Under Legal Challenge
Fifty-seven percent of all adult-use licenses have been awarded to Social and Economic Equity applicants. Three hundred twenty-five active CAURD licensees hold conditional licenses extended through December 31, 2026. The equity framework is not a policy footnote — it is the structural foundation of New York's licensing architecture.
That foundation is now under direct legal challenge. On March 25, 2026, a federal judge in the Northern District of New York ruled that a constitutional challenge to the equity-based licensing system will proceed. The claim: that prioritizing applicants with prior marijuana convictions violates the dormant Commerce Clause. The ruling followed an August 2025 Second Circuit decision holding that the Commerce Clause applies to cannabis licensing.
If the challenge succeeds, it would not eliminate existing licenses. But it would reshape the competitive entry conditions for every future retail applicant across the entire New York market. For operators planning expansion, this case is not background noise. It is the variable that determines the competitive landscape of 2027 and beyond.
The Medical Program: Structural Cannibalization
While adult-use sales accelerate, medical cannabis revenue is declining. Medical sales posted $95.5 million through November 2025 — down 30% year-over-year from $140 million in 2024. The pattern is consistent with every state that has launched adult-use alongside an existing medical program: consumers migrate to the recreational market, and the medical channel contracts.
This is not a policy failure. It is a structural inevitability. But it does raise a question the state has not yet addressed: what is the long-term role of the medical program when adult-use access is effectively universal? The 19 registered organizations operating medical dispensaries are watching their patient base erode while the adult-use market they were initially excluded from continues to expand.
Supply Constraints and Cultivation Expansion
The market has inverted. In 2023, New York had too much product and too few stores. In 2026, demand is outpacing supply. The Cannabis Control Board responded at the March 5 meeting by voting to allow existing cultivators to apply to move up one tier to increase canopy. The state has licensed 560 cultivators to date, but not all are at full capacity — the 9.1 million square feet of licensed canopy is not fully activated.
Supply expansion through existing cultivator upgrades is the fastest lever available, but it operates on agricultural timelines, not retail timelines. Product availability constraints are already visible in dispensary inventory patterns and will intensify through the second half of 2026 if cultivation expansion does not keep pace with 610+ operational storefronts.
The Category Signal: Beverages
Within the product mix, one category is outperforming every forecast: cannabis beverages. Sales reached $2.48 million in February 2026, up 88.2% year-over-year. Unit sales more than doubled at 134.1% growth. Within the segment, tea and coffee products posted 223.8% sales growth and 627.2% unit growth.
Beverage is not the largest category. Flower and pre-rolls dominate. But beverage is the fastest-moving signal in the market — and its growth trajectory suggests a consumer base that is expanding beyond traditional cannabis users into format-driven, occasion-based consumption. This is the category that bridges cannabis into mainstream consumer behavior.
What This Market Demands
New York's cannabis market is not broken. It is not struggling. It is growing faster than any large state market in the country, with $3.3 billion in cumulative sales, 623 dispensaries, and a licensing apparatus that has issued over 2,200 licenses in under four years.
But it is growing without margin clarity. Without resolution on the Commerce Clause challenge. Without supply infrastructure that matches demand velocity. And without a unified data layer that reconciles what one state system says against another.
TCRB exists to build that layer. We do not advocate for policy positions. We do not rank dispensaries by aesthetics. We reconcile market data that was never designed to be reconciled, and we publish what we find.
The $3.3 billion is not a talking point. It is the starting line.
The Cannabis Review Board. System of record.